AML Leukemia Prognosis
AML Leukemia Prognosis: Acute myelogenous leukemia or acute myeloid leukemia (AML) can be defined as a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells and as rapidly progressive neoplasm resulting from hematopoietic precursors, or myeloid stem tissue, that give rise to monocytes, platelets, granulocytes and erythrocytes.
AML leukemia symptoms are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in normal white blood cells, red blood cells and platelets. These symptoms include increased risk of infection, shortness of breath, fatigue and easy bruising or bleeding.
AML leukemia symptoms are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in normal white blood cells, red blood cells and platelets. These symptoms include increased risk of infection, shortness of breath, fatigue and easy bruising or bleeding.
Copyright 2011 AcuteLymphoblasticLeukemia.Org
AcuteLymphoblasticLeukemia.Org
Custom Search
Custom Search
aml leukemia prognosis
AML Leukemia Prognosis and Diagnosis
Prognosis for AML leukemia and Diagnosis is most accurately provided by pretreatment assessment of the immunophenotype, morphology and underlying chromosomal and molecular aberrations responsible for the leukemia disease. AML leukemia prognosis (chance of recovery), option of treatment regimen, and MRD monitoring are evolving to depend on identification to gene mutations that aren’t observed on typical cytogenetic analysis. AML leukemias are classified by morphology and cytochemical staining. Acute myeloid leukemia (AML) is a curable disease; the chance of cure for a specific patient with AML depends on a number of prognostic factors. These factors include Cytogenetics, Myelodysplastic syndrome and other prognostic markers.
Cytogenetics
Cytogenetics (chromosomal structure of the leukemic cell) is the most important acute myelogenous leukemia AML prognosis factor. Approximately half of patients with AML leukemia have "normal" cytogenetics; they will be classified an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor AML leukemia prognosis and a high possibility of relapse after treatment.
Good risk Category: Abnormality – t (8; 21, t (15; 17), inv (16) will be 70 percent of 5-year survival rate and 33 percent of relapse rate.
Intermediate Risk Category: Abnormality – Normal, +8, +21, del (7q), del (9q), Abnormal 11q23, all other structural or numerical changes will be 48 percent of 5-year survival rate and 50 percent of relapse rate.
Poor Risk Category: Abnormality: -5, -7, del (5q), Abnormal 3q, Complex cytogenetics will be 15 percent of 5-year survival rate and 78 percent of relapse rate.
Myelodysplastic syndrome
Myelodysplastic syndrome: AML which arises from a pre-existing myeloproliferative disease (so-called secondary AML) or myelodysplastic syndrome has a worse AML leukemia prognosis, as does treatment-related AML arising after chemotherapy for another previous malignancy.
Other prognostic markers
The patients with AML leukemia who elevated lactate dehydrogenase level and age more than 60 years-old were associated with poor risk category. As with most forms of cancer, performance status plays a major role in AML leukemia prognosis as well.
AML Leukemia Prognosis related tags and keywords for more search
acute myelogenous leukemia aml prognosis, adult acute myeloid leukemia, blood and bone marrow, childhood acute myeloid leukemia, anemia with excess blasts, acute aml leukemia prognosis, which the bone marrow, type of white blood, bone marrow are used, , adult acute myeloid, childhood acute myeloid, other myeloid malignancies, chemotherapy, cytopenia, prognosis for aml leukemia
Cytogenetics
Cytogenetics (chromosomal structure of the leukemic cell) is the most important acute myelogenous leukemia AML prognosis factor. Approximately half of patients with AML leukemia have "normal" cytogenetics; they will be classified an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor AML leukemia prognosis and a high possibility of relapse after treatment.
Good risk Category: Abnormality – t (8; 21, t (15; 17), inv (16) will be 70 percent of 5-year survival rate and 33 percent of relapse rate.
Intermediate Risk Category: Abnormality – Normal, +8, +21, del (7q), del (9q), Abnormal 11q23, all other structural or numerical changes will be 48 percent of 5-year survival rate and 50 percent of relapse rate.
Poor Risk Category: Abnormality: -5, -7, del (5q), Abnormal 3q, Complex cytogenetics will be 15 percent of 5-year survival rate and 78 percent of relapse rate.
Myelodysplastic syndrome
Myelodysplastic syndrome: AML which arises from a pre-existing myeloproliferative disease (so-called secondary AML) or myelodysplastic syndrome has a worse AML leukemia prognosis, as does treatment-related AML arising after chemotherapy for another previous malignancy.
Other prognostic markers
The patients with AML leukemia who elevated lactate dehydrogenase level and age more than 60 years-old were associated with poor risk category. As with most forms of cancer, performance status plays a major role in AML leukemia prognosis as well.
AML Leukemia Prognosis related tags and keywords for more search
acute myelogenous leukemia aml prognosis, adult acute myeloid leukemia, blood and bone marrow, childhood acute myeloid leukemia, anemia with excess blasts, acute aml leukemia prognosis, which the bone marrow, type of white blood, bone marrow are used, , adult acute myeloid, childhood acute myeloid, other myeloid malignancies, chemotherapy, cytopenia, prognosis for aml leukemia